GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Standard BioTools Inc (STU:FLB) » Definitions » EV-to-EBITDA

Standard BioTools (STU:FLB) EV-to-EBITDA : -7.51 (As of May. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Standard BioTools EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Standard BioTools's enterprise value is €528.50 Mil. Standard BioTools's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-70.36 Mil. Therefore, Standard BioTools's EV-to-EBITDA for today is -7.51.

The historical rank and industry rank for Standard BioTools's EV-to-EBITDA or its related term are showing as below:

STU:FLB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.76   Med: -9.85   Max: 2.33
Current: -10.45

During the past 13 years, the highest EV-to-EBITDA of Standard BioTools was 2.33. The lowest was -82.76. And the median was -9.85.

STU:FLB's EV-to-EBITDA is ranked worse than
100% of 114 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.35 vs STU:FLB: -10.45

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), Standard BioTools's stock price is €2.20. Standard BioTools's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.881. Therefore, Standard BioTools's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Standard BioTools EV-to-EBITDA Historical Data

The historical data trend for Standard BioTools's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools EV-to-EBITDA Chart

Standard BioTools Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.25 -13.70 -8.69 -0.17 -2.95

Standard BioTools Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -1.71 -3.63 -2.95 -

Competitive Comparison of Standard BioTools's EV-to-EBITDA

For the Diagnostics & Research subindustry, Standard BioTools's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Standard BioTools's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Standard BioTools's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Standard BioTools's EV-to-EBITDA falls into.



Standard BioTools EV-to-EBITDA Calculation

Standard BioTools's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=528.500/-70.36
=-7.51

Standard BioTools's current Enterprise Value is €528.50 Mil.
Standard BioTools's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-70.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Standard BioTools  (STU:FLB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Standard BioTools's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.20/-0.881
=At Loss

Standard BioTools's share price for today is €2.20.
Standard BioTools's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.881.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Standard BioTools EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Standard BioTools's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Standard BioTools (STU:FLB) Business Description

Traded in Other Exchanges
Address
2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080
Standard BioTools Inc manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. The company's segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Standard BioTools (STU:FLB) Headlines

No Headlines